Clinical Trial Update: A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Ridaforolimus (MK-8669) effect on QTc interval in participants with metastatic or locally advanced cancer has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic or Locally Advanced Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-05-06